AR123121A1 - Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillo saturado y su uso farmacéutico - Google Patents

Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillo saturado y su uso farmacéutico

Info

Publication number
AR123121A1
AR123121A1 ARP190100481A ARP190100481A AR123121A1 AR 123121 A1 AR123121 A1 AR 123121A1 AR P190100481 A ARP190100481 A AR P190100481A AR P190100481 A ARP190100481 A AR P190100481A AR 123121 A1 AR123121 A1 AR 123121A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
coo
independently
group
Prior art date
Application number
ARP190100481A
Other languages
English (en)
Inventor
Masahiro Yokota
Noriyoshi Seki
Eiichi Watanabe
Shingo Fujioka
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR123121A1 publication Critical patent/AR123121A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula [1] en donde R¹ es (1) alquilo C₁₋₈, (2) halo-alquilo C₁₋₈, (3) cicloalquilo C₃₋₈ opcionalmente sustituido con 1 a 3 sustituyentes iguales o diferentes seleccionados del grupo A¹ o (4) cicloalquil C₃₋₈-alquilo C₁₋₄ en donde el resto de cicloalquilo C₃₋₈ puede estar opcionalmente sustituido con 1 a 3 sustituyentes iguales o diferentes seleccionados del grupo A¹, el grupo A¹ es (1) halógeno, (2) alquilo C₁₋₄ y (3) halo-alquilo C₁₋₄, X¹ es (1) un enlace o (2) -O-, R² es (1) hidrógeno o (2) halógeno, R³ es (1) hidrógeno o (2) -Y³-COO-R³⁰, Y³ es (1) alquileno C₁₋₈, (2) cicloalquileno C₃₋₈, (3) cicloalquileno C₅₋₈ en puente o (4) arileno C₆₋₁₄, R³⁰ es (1) hidrógeno o (2) alquilo C₁₋₄, X² es (1) =C(R⁴)- o (2) =N-, R⁴ es (1) hidrógeno o (2) alquilo C₁₋₄, X³ es (1) -C(R⁵)(R⁶)-, X⁴ es (1) un enlace o (2) -C(R⁷)(R⁸)-, X⁵ es (1) -C(R⁹)(R¹⁰)-, (2) -N(R¹¹)- o (3) -O-, R⁵ y R⁶ son cada uno, de modo independiente, (1) hidrógeno, (2) alquilo C₁₋₄, (3) halo-alquilo C₁₋₄, (4) ciano-alquilo C₁₋₄ o (5) alquilo C₁₋₄ sustituido con un sustituyente seleccionado del grupo que consiste en -O-R⁵¹, -CO-R⁶¹, -COO-R⁵², -N(R⁷¹)(R⁷²), -CO-N(R⁷³)(R⁷⁴), -N(R⁷⁵)-CO-R⁶², -N(R⁷⁶)-COO-R⁵³ y - O-S(O)₂-R⁶³, R⁷, R⁸, R⁹ y R¹⁰ son cada uno, de modo independiente, (1) hidrógeno, (2) halógeno, (3) ciano, (4) hidroxi, (5) alquilo C₁₋₄, (6) halo-alquilo C₁₋₄, (7) ciano-alquilo C₁₋₄, (8) alcoxi C₁₋₄ o (9) alquilo C₁₋₄ sustituido con un sustituyente seleccionado del grupo que consiste en -O-R⁵¹, -CO-R⁶¹, -COO-R⁵², -N(R⁷¹)(R⁷²), -CO-N(R⁷³)(R⁷⁴), -N(R⁷⁵)-CO-R⁶², -N(R⁷⁶)-COO-R⁵³ y -O-S(O)₂-R⁶³, R⁵¹, R⁵² y R⁵³ son cada uno, de modo independiente, (1) hidrógeno, (2) alquilo C₁₋₄ o (3) aril C₆₋₁₄-alquilo C₁₋₄, R⁶¹, R⁶² y R⁶³ son cada uno, de modo independiente, (1) alquilo C₁₋₄, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵ y R⁷⁶ son cada uno, de modo independiente, (1) hidrógeno o (2) alquilo C₁₋₄, R¹¹ es (1) -CO-R¹¹¹ o (2) -COO-R¹¹², R¹¹¹ es (1) alquilo C₁₋₄, R¹¹² es (1) alquilo C₁₋₄ o una de sus sales farmacéuticamente aceptables.
ARP190100481A 2018-02-28 2019-02-27 Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillo saturado y su uso farmacéutico AR123121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018035601 2018-02-28

Publications (1)

Publication Number Publication Date
AR123121A1 true AR123121A1 (es) 2022-11-02

Family

ID=67805013

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100481A AR123121A1 (es) 2018-02-28 2019-02-27 Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillo saturado y su uso farmacéutico

Country Status (18)

Country Link
US (2) US20190300490A1 (es)
EP (1) EP3760619B1 (es)
JP (1) JP7200005B2 (es)
KR (1) KR20200127177A (es)
CN (1) CN111741948B (es)
AR (1) AR123121A1 (es)
AU (1) AU2019228916A1 (es)
BR (1) BR112020016784A2 (es)
CA (1) CA3088000A1 (es)
CL (1) CL2020002188A1 (es)
IL (1) IL276326A (es)
MX (1) MX2020008929A (es)
PE (1) PE20210447A1 (es)
PH (1) PH12020551342A1 (es)
RU (1) RU2020131405A (es)
SG (1) SG11202007119UA (es)
TW (1) TW202000652A (es)
WO (1) WO2019167982A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
JP7065989B2 (ja) 2018-02-28 2022-05-12 ノバルティス アーゲー インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての１０－（ジ（フェニル）メチル）－４－ヒドロキシ－８，９，９ａ，１０－テトラヒドロ－７Ｈ－ピロロ［１’，２’：４，５］ピラジノ［１，２－ｂ］ピリダジン－３，５－ジオン誘導体および関連化合物
CN111741948B (zh) 2018-02-28 2023-11-10 日本烟草产业株式会社 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
AU2008263207B2 (en) 2007-06-01 2013-10-03 Merck Sharp & Dohme Corp. Gamma secretase modulators
MX2010011563A (es) 2008-04-22 2010-11-12 Schering Corp Compuestos 2-imino-3-metil pirrolo pirimidinona fenil-sustituidos como inhibidores de enzima de escision de proteina precursora amiloide sitio beta-1, composiciones y su uso.
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
EP3223820B1 (en) 2014-11-25 2020-07-22 Merck Sharp & Dohme Corp. 3-methyl-2-imino-hexahydro-1h-pyrano[3,4-d]pyrimidin-4-one compounds as bace inhibitors, compositions, and their use
AR102972A1 (es) 2014-12-12 2017-04-05 Japan Tobacco Inc Compuestos de dihidropirimidin-2-ona y su uso médico
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
CN111741948B (zh) 2018-02-28 2023-11-10 日本烟草产业株式会社 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途

Also Published As

Publication number Publication date
PE20210447A1 (es) 2021-03-08
KR20200127177A (ko) 2020-11-10
CL2020002188A1 (es) 2020-12-18
TW202000652A (zh) 2020-01-01
EP3760619A4 (en) 2021-07-07
JP2019151624A (ja) 2019-09-12
US11834421B2 (en) 2023-12-05
JP7200005B2 (ja) 2023-01-06
CA3088000A1 (en) 2019-09-06
US20190300490A1 (en) 2019-10-03
WO2019167982A1 (ja) 2019-09-06
MX2020008929A (es) 2020-10-01
AU2019228916A1 (en) 2020-07-02
US20220119355A1 (en) 2022-04-21
EP3760619B1 (en) 2023-10-25
BR112020016784A2 (pt) 2021-01-12
PH12020551342A1 (en) 2021-06-21
IL276326A (en) 2020-09-30
EP3760619A1 (en) 2021-01-06
RU2020131405A (ru) 2022-03-24
SG11202007119UA (en) 2020-08-28
CN111741948B (zh) 2023-11-10
CN111741948A (zh) 2020-10-02

Similar Documents

Publication Publication Date Title
AR123121A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillo saturado y su uso farmacéutico
AR114950A1 (es) Compuestos de benzamida
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR058198A1 (es) Derivados de morfolina y composiciones farmaceuticas
AR109709A1 (es) Inhibidores de la fosfatidilinositol 3-quinasa
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR108356A1 (es) Derivados aromáticos de sulfonamida
AR116109A1 (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR110405A1 (es) Compuestos
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR119018A1 (es) Inhibidores de proteína quinasas dependientes de adn
AR097279A1 (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
AR114828A1 (es) Compuestos de pteridinona y sus usos
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
AR108185A1 (es) Amidas terciarias y método para su uso
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR126693A1 (es) Compuestos de pirazolopiridinona
AR093035A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR102972A1 (es) Compuestos de dihidropirimidin-2-ona y su uso médico
AR119971A1 (es) Derivados de piridazin-3(2h)-ona fusionados con azol
AR122704A1 (es) Derivados de amidopirimidona
AR114564A1 (es) DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal